Julie Patterson, PharmD, PhD, senior director of research at the National Pharmaceutical Council, discussed potential impact of the Inflation Reduction Act of 2022 (IRA) on small molecule drug research and development investments toward subsequent indications.
Eye On The IRA | Health Affairs healthaffairs.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthaffairs.org Daily Mail and Mail on Sunday newspapers.
If we are to achieve the clinical and economic benefits of primary care and care continuity, the implementation and evaluation of strategies that reward clinicians and patients are warranted.
The Inflation Reduction Act will likely change incentives surrounding single-indication launches and postapproval research for additional indications in small molecule drugs, affecting patient access.
After Pfizer's exit, UCB splits from industry trade group BIO fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.